medigraphic.com
Instituto Nacional de Salud Pública

2022, Number 5

<< Back

salud publica mex 2022; 64 (5)

Clinical Practice Guideline for the early detection and timely referral of lung cancer patients

Arroyo-Hernández M, Alva-López LF, Rendón A, Barroso-Villafuerte FR, Báez-Saldaña R, Corona-Cruz JF, Farfán-Salazar G, Guerrero-Ixtlahuac J, Castillo-González P, Salmon-Demongin A, Zaldívar-Crosby G, Bolaño-Guerra LM, Zavala-Cruz GG, Sánchez-Gutiérrez JA, Rendón-Ramírez EJ, Magdaleno-Maldonado GE, Olivares-Torres CA, López-Saucedo RA, Lizardo AE, Ortiz-Vázquez S, Vázquez-García J, Montes-Narváez G, Pacheco-Juárez M, Arrieta O

Language: Spanish
References: 46
Page: 530-538
PDF size: 298.65 Kb.


ABSTRACT

Objective. To provide recommendations for the early lung cancer diagnosis in patients with risk factors at primary care and their timely referral. Materials and methods. This clinical practice guideline (CPG) was developed to establish recommendations based on the best available evidence and agreed upon by a group of experts representing different health sectors. A multidisciplinary group of experts that conformed to the Guideline Development Group (GDG) and conducted detailed scientific evidence research that answered the clinical research questions. The modified Delphi Panel was used to achieve an adequate consensus on the recommendations contained in this CPG. Results. Fourteen recommendations were generated following the standards of a CPG. Conclusion. LC represents a public health concern in México. Therefore, this guideline establishes recommendations to support decision-making regarding early detection and referral of LC in primary care health services.


REFERENCES

  1. Organización Panamericana de la Salud. La epidemia del tabaquismo, losgobiernos y los aspectos económicos del control del tabaco. Washington,DC: OPS, 2000. https://iris.paho.org/handle/10665.2/2814

  2. Arrieta O, Lazcano E. Cáncer de pulmón. El peso de la enfermedad yavances en el diagnóstico y tratamiento. 2019;61(3):217-8. https://doi.org/10.21149/10660

  3. Arrieta O, Quintana-Carrillo RH, Ahumada-Curiel G, Corona-Cruz JF,Correa-Acevedo E, Zinser-Sierra J, et al. Medical care costs incurred bypatients with smoking-related non-small cell lung cancer treated at theNational Cancer Institute of Mexico. Tob Induc Dis. 2014;12(1):25. https://doi.org/10.1186/s12971-014-0025-4

  4. US Preventive Services Task Force. Screening for Lung Cancer: USPreventive Services Task Force Recommendation Statement. JAMA.2021;325(10):962-70. https://doi.org/10.1001/jama.2021.1117

  5. National Lung Screening Trial Research Team. Reduced lung-cancermortality with low-dose computed tomographic screening. N Engl J Med.2011;365(5):395-409. https://doi.org/10.1056/NEJMoa1102873

  6. Blanchon T, Bréchot JM, Grenier PA, Ferretti GR, Lemarié E, MilleronB, et al. Baseline results of the Depiscan study: a French randomizedpilot trial of lung cancer screening comparing low dose CT scan (LDCT)and chest X-ray (CXR). Lung Cancer. 2007;58(1):50-8. https://doi.org/10.1016/j.lungcan.2007.05.009

  7. Gohagan JK, Marcus PM, Fagerstrom RM, Pinsky PF, Kramer BS, ProrokPC, et al. Final results of the Lung Screening Study, a randomized feasibilitystudy of spiral CT versus chest X-ray screening for lung cancer. LungCancer. 2005;47(1):9-15. https://doi.org/10.1016/j.lungcan.2004.06.007

  8. Infante M, Cavuto S, Lutman FR, Passera E, Chiarenza M, Chiesa G, et al.Long-term follow-up results of the DANTE trial, a randomized study oflung cancer screening with spiral computed tomography. Am J Respir CritCare Med. 2015;191(10):1166-75. https://doi.org/10.1164/rccm.201408-1475OC

  9. Wille MM, Dirksen A, Ashraf H, Saghir Z, Bach KS, Brodersen J, et al. Resultsof the randomized danish lung cancer screening trial with focus onhigh-risk profiling. Am J Respir Crit Care Med. 2016;193(5):542-51. https://doi.org/10.1164/rccm.201505-1040OC

  10. de Koning HJ, van der Aalst CM, de Jong PA, Scholten ET, NackaertsK, Heuvelmans MA. Reduced lung-cancer mortality with volume CTscreening in a randomized trial. N Engl J Med. 2020;382(6):503-13. https://doi.org/10.1056/NEJMoa1911793

  11. Paci E, Puliti D, Lopes-Pegna A, Carrozzi L, Picozzi G, Falaschi F, et al.Mortality, survival and incidence rates in the ITALUNG randomised lungcancer screening trial. Thorax. 2017;72(9):825-31. https://doi.org/10.1136/thoraxjnl-2016-209825

  12. Pastorino U, Silva M, Sestini S, Sabia F, Boeri M, Cantarutti A, et al.Prolonged lung cancer screening reduced 10-year mortality in the MILDtrial: new confirmation of lung cancer screening efficacy. Ann Oncol.2019;30(7):1162-9. https://doi.org/10.1093/annonc/mdz117

  13. Becker N, Motsch E, Trotter A, Heussel CP, Dienemann H, Schnabel PA,et al. Lung cancer mortality reduction by LDCT screening-results fromthe randomized German LUSI trial. Int J Cancer. 2020;146(6):1503-13.https://doi.org/10.1002/ijc.32486

  14. Field JK, Duffy SW, Baldwin DR, Brain KE, Devaraj A, Eisen T, et al. TheUK Lung Cancer Screening Trial: a pilot randomised controlled trial oflow-dose computed tomography screening for the early detection of lungcancer. Health Technol Assess. 2016;20(40):1-146. https://doi.org/10.3310/hta20400

  15. dos Santos RS, Franceschini JP, Caruso-Chate R, Ghefter MC, Kay F,Trajano AL, et al. Do current lung cancer screening guidelines apply forpopulations with high prevalence of granulomatous disease? Results fromthe First Brazilian Lung Cancer Screening Trial (BRELT1). Ann Thorac Surg.2016;101(2):481-6. https://doi.org/10.1016/j.athoracsur.2015.07.013

  16. Jonas DE, Reuland DS, Reddy SM, Nagle M, Clark SD, Weber RP.Screening for lung cancer with low-dose computed tomography: updatedevidence report and systematic review for the US Preventive ServicesTask Force. JAMA. 2021;325(10):971-87. https://doi.org/10.1001/jama.2021.0377

  17. Kluge HHP. Screening programmes: a short guide. Increase effectiveness,maximize benefits and minimize harm: Copenhagen: WHO RegionalOffice for Europe; 2020. [citado mayo 2022]. Disponible en: https://apps.who.int/iris/bitstream/handle/10665/330829/9789289054782-eng.pdf

  18. Tækker M, Kristjánsdóttir B, Graumann O, Laursen CB, Pietersen PI.Diagnostic accuracy of low-dose and ultra-low-dose CT in detection ofchest pathology: a systematic review. Clin Imaging. 2021;74:139-48. https://doi.org/10.1016/j.clinimag.2020.12.04

  19. Lindson N, Pritchard G, Hong B, Fanshawe TR, Pipe A, Papadakis S.Strategies to improve smoking cessation rates in primary care. CochraneDatabase Syst Rev. 2021;9:CD011556. https://doi.org/10.1002/14651858.CD011556.pub2

  20. Evans WK, Gauvreau CL, Flanagan WM, Memon S, Ein-Yong JH, GoffinJR. Clinical impact and cost-effectiveness of integrating smoking cessationinto lung cancer screening: a microsimulation model. CMAJ Open.2020;8(3):E585-E92. https://doi.org/10.9778/cmajo.20190134

  21. Thunnissen FB. Sputum examination for early detection of lungcancer. J Clin Pathol. 2003;56(11):805-10. https://doi.org/10.1136/jcp.56.11.805

  22. Fontana RS, Sanderson DR, Taylor WF, Miller WE, Muhm JR, UhlenhoppMA. Early lung cancer detection: results of the initial (prevalence) radiologicand cytologic screening in the Mayo Clinic study. Am Rev Respir Dis.1984;130(4):561-5. https://doi.org/10.1164/arrd.1984.130.4.561

  23. Flehinger BJ, Melamed MR, Zaman MB, Heelan RT, Perchick WB,Martini N. Early lung cancer detection: results of the initial (prevalence)radiologic and cytologic screening in the Memorial Sloan-Ketteringstudy. Am Rev Respir Dis. 1984;130(4):555-60. https://doi.org/10.1164/arrd.1984.130.4.555

  24. Frost JK, Ball WC, Levin ML, Tockman MS, Baker RR, Carter D, et al.Early lung cancer detection: results of the initial (prevalence) radiologicand cytologic screening in the Johns Hopkins study. Am Rev Respir Dis.1984;130(4):549-54. https://doi.org/10.1164/arrd.1984.130.4.549

  25. Cortes-Jofre M, Rueda JR, Corsini-Muñoz G, Fonseca-Cortés C, CaraballosoM, Bonfill-Cosp X. Drugs for preventing lung cancer in healthypeople. Cochrane Database Syst Rev. 2020;3:CD002141. https://doi.org/10.1002/14651858.CD002141.pub3

  26. Fritz H, Kennedy D, Fergusson D, Fernandes R, Doucette S, CooleyK, et al. Vitamin A and retinoid derivatives for lung cancer: a systematicreview and meta analysis. PLoS One. 2011;6(6):e21107. https://doi.org/10.1371/journal.pone.0021107

  27. Myung SK, Kim Y, Ju W, Choi HJ, Bae WK. Effects of antioxidant supplementson cancer prevention: meta-analysis of randomized controlled trials.Ann Oncol. 2010;21(1):166-79. https://doi.org/10.1093/annonc/mdp286

  28. van Zandwijk N, Dalesio O, Pastorino U, de Vries N, van Tinteren H.EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine inpatients with head and neck cancer or lung cancer. For the EUropeanOrganization for Research and Treatment of Cancer Head and Neck andLung Cancer Cooperative Groups. J Natl Cancer Inst. 2000;92(12):977-86.https://doi.org/10.1093/jnci/92.12.977

  29. Rock CL, Thomson C, Gansler T, Gapstur SM, McCullough ML, PatelAV, et al. American Cancer Society guideline for diet and physical activityfor cancer prevention. CA Cancer J Clin. 2020;70(4):245-71. https://doi.org/10.3322/caac.21591

  30. Álvarez-Villar F, Trueba-Muguruza I, Sanchis-Belda J, Molins López-RodóL, Rodríguez-Suárez PM, Sánchez de Cos-Escuín J, et al. Recommendationsof the Spanish Society of Pneumology and Thoracic Surgery on the diagnosisand treatment of non-small-cell lung cancer. Arch Bronconeumol.2016;52(suppl 1):2-62. https://doi.org/10.1016/s0300-2896(16)30198-3

  31. Arrieta O, Guzman-de Alba E, Alba-López LF, Acosta-Espinoza A, Alatorre-Alexander J, Alexander-Meza JF, et al. National consensus of diagnosisand treatment of non-small cell lung cancer. Rev Invest Clin. 2013;65(suppl1):S5-84, https://www.ncbi.nlm.nih.gov/pubmed/24459776

  32. Dwyer-Hemmings L, Fairhead C. The diagnostic performance of chestradiographs for lung malignancy in symptomatic primary-care populations:A systematic review and meta-analysis. BJR Open. 2021;3(1):20210005.https://doi.org/10.1259/bjro.20210005

  33. Baldwin DR, White B, Schmidt-Hansen M, Champion AR, MelderAM. Diagnosis and treatment of lung cancer: summary of updated NICEguidance. BMJ. 2011;342:d2110. https://doi.org/10.1136/bmj.d2110

  34. MacMahon H, Naidich DP, Goo JM, Lee KS, Leung AN, Maro JR,et al. Guidelines for Management of Incidental Pulmonary NodulesDetected on CT Images: From the Fleischner Society 2017. Radiology.2017;284(1):228-43. https://doi.org/10.1148/radiol.2017161659

  35. Bueno J, Landeras L, Chung JH. Updated Fleischner Society Guidelinesfor Managing Incidental Pulmonary Nodules: common questionsand challenging scenarios. radiographics. 2018;38(5):1337-50. https://doi.org/10.1148/rg.2018180017

  36. Larici AR, Farchione A, Franchi P, Ciliberto M, Cicchetti G, CalandrielloL, et al. Lung nodules: size still matters. Eur Respir Rev.2017;26(146):170025. https://doi.org/10.1183/16000617.0025-2017

  37. Cruickshank A, Stieler G, Ameer F. Evaluation of the solitary pulmonarynodule. Intern Med J. 2019;49(3):306-15. https://doi.org/10.1111/imj.14219

  38. Khan A, Al-Jahdali H, Allen C, Irion K, Ghanem S, Koteyar S. The calcifiedlung nodule: What does it mean? Ann Thorac Med. 2010;5(2):67-79.https://doi.org/10.4103/1817-1737.62469

  39. Gould MK, Fletcher J, Iannettoni MD, Lynch WR, Midthun DE, NaidichDP, et al. Evaluation of patients with pulmonary nodules: when is it lungcancer?: ACCP evidence-based clinical practice guidelines (2nd ed). Chest.2007;132(suppl 3):108S-30S. https://doi.org/10.1378/chest.07-1353

  40. Planchard D, Popat S, Kerr K, Smit EF, Faive-Finn C, Mok TS, et al.Correction to: “Metastatic non-small cell lung cancer: ESMO ClinicalPractice Guidelines for diagnosis, treatment and follow-up”. Ann Oncol.2019;30(5):863-70. https://doi.org/10.1093/annonc/mdy474

  41. Shi Y, Wu S, Ma S, Lyu Y, Xu H, Deng L, Chen X. Comparison betweenwedge resection and lobectomy/segmentectomy for early-stage nonsmallcell lung cancer: a bayesian meta-analysis and systematic review.Ann Surg Oncol. 2022;29(3):1868-79. https://doi.org/10.1245/s10434-021-10857-7

  42. Bukowski A, Chávarri-Guerra Y, Goss PE. The potential role ofpatient navigation in low- and middle-income countries for patients withcancer. JAMA Oncol. 2016;2(8):994-5. https://doi.org/10.1001/jamaoncol.2016.0766

  43. Salomaa ER, Sällinen S, Hiekkanen H, Liippo K. Delays in the diagnosisand treatment of lung cancer. Chest. 2005;128(4):2282-8. https://doi.org/10.1378/chest.128.4.2282

  44. Chavarri-Guerra Y, Soto-Perez-de-Celis E, Ramos-López W, SanMiguel-de Majors SL, Sanchez-Gonzalez J, Ahumada-Tamayo S, et al. Patientnavigation to enhance access to care for underserved patients with asuspicion or diagnosis of cancer. Oncologist. 2019;24(9):1195-200. https://doi.org/10.1634/theoncologist.2018-0133

  45. Ponholzer F, Kroepfl V, Ng C, Maier H, Kocher F, Luccarini P, et al.Delay to surgical treatment in lung cancer patients and its impact onsurvival in a video-assisted thoracoscopic lobectomy cohort. Sci Rep.2021;11(1):4914. https://doi.org/10.1038/s41598-021-84162-4

  46. Hall H, Tocock A, Burdett S, Fisher D, Ricketts WM, Robson J, et al.Association between time-to-treatment and outcomes in non-small celllung cancer: a systematic review. Thorax. 2022;77(8):762-8. https://doi.org/10.1136/thoraxjnl-2021-216865




2020     |     www.medigraphic.com